Key Highlights

  • Absci shares closed at $10.35 today, up 6.21%.
  • The company announced details for a planned Phase 2 STORYLINE trial evaluating ABS-201, an AI-designed antibody, for endometriosis.
  • The trial is expected to enroll approximately 150 patients across 10 or more countries, with initiation anticipated in mid-2027.
  • ABS-201 is also being investigated separately as a potential treatment for pattern hair loss in the company's ongoing HEADLINE trial.

STORYLINE Trial Details Drive Shares Higher

Absci (NASDAQ:ABSI) shares closed higher today after the company announced additional details for its planned Phase 2 STORYLINE clinical trial evaluating ABS-201, an investigational anti-prolactin receptor antibody engineered with the company's generative AI platform, for endometriosis. The planned double-blind, placebo-controlled trial would assess efficacy and safety in patients with surgically diagnosed endometriosis and moderate to severe associated pain, with the company anticipating enrollment of approximately 150 patients across 10 or more countries.

Dosing Strategy Will Draw on Ongoing Hair Loss Trial Data

Absci said it anticipates initiating the STORYLINE trial in mid-2027, with safety, tolerability and pharmacokinetic data from its ongoing HEADLINE trial evaluating ABS-201 for pattern hair loss informing the dose selection for the endometriosis study. The company is designing STORYLINE as a dose-ranging trial testing two or three dose levels, to be confirmed following review of the HEADLINE data. The company's chief medical officer said prolactin receptor blockade offers a fundamentally different, non-hormonal approach to a condition affecting roughly one in ten women of reproductive age.

An AI-First Approach to Drug Discovery

Absci is a clinical-stage biopharmaceutical company headquartered in Vancouver, Washington, that combines generative AI models with a synthetic biology data engine through its Integrated Drug Creation platform to design novel therapeutics. Beyond ABS-201, the company's pipeline includes earlier-stage programs and collaborations with pharmaceutical, biotech and academic partners, with the endometriosis program representing an expansion of the company's use of the same antibody candidate across two distinct therapeutic areas.